Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-03-15
2011-03-15
Fetterolf, Brandon J (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S629000
Reexamination Certificate
active
07906519
ABSTRACT:
Methods for concomitant administration of colchicine together with one or more second active agents, e.g., ketoconazole and ritonavir, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for concomitant administration of colchicine together with second active agents are also provided.
REFERENCES:
patent: 5426224 (1995-06-01), Lee et al.
patent: 5914332 (1999-06-01), Sham et al.
patent: 5968972 (1999-10-01), Broder et al.
patent: 6037157 (2000-03-01), Norbeck et al.
patent: 6245805 (2001-06-01), Broder et al.
patent: 6896900 (2005-05-01), Gosselin et al.
patent: 7601758 (2009-10-01), Davis
patent: 7619004 (2009-11-01), Davis
www.drugs.com (available online at http://www.drugs.com/dosage/colchicine.html) accessed Sep. 20, 2010.
Heeswijk et al (AIDS 14:F103-F110, 2000).
Horn et al (Pharmacy Times, May 2006, p. 111).
www.Rx-s.net (last revised Aug. 2, 2005).
U.S. Appl. No. 12/372,046, filed Feb. 17, 2009; Non-Final Office Action dated Jan. 26, 2010; 30 pages.
U.S. Appl. No. 12/372,046, filed Feb. 17, 2009; Non-Final Office Action dated May 18, 2009; 9 pages.
U.S. Appl. No. 12/372,046, filed Feb. 17, 2009; Final-Office Action dated Sep. 11, 2009; 10 pages.
U.S. Appl. No. 12/372,046, filed Feb. 17, 2009; Non-Final Office Action dated Jul. 14, 2009; 10 pages.
U.S. Appl. No. 12/688,038, filed Jan. 15, 2010; Final Office Action dated Jun. 28, 2010; 33 pages.
U.S. Appl. No. 12/688,038, filed Jan. 15, 2010; Non-Final Office Action dated Apr. 2, 2010; 36 pages.
Colchicine-Probenecid, Colchicine-Probenecid—Side effect guide, warning symptoms; http://www.healthgrades.com/drug-ratings/drug/sideeffects/2207/Colchicine-Probenecid; printed Dec. 2, 2009; 2 pages.
Colcyrs, Prescribing Information, www.colcrys.com/assets/pdf/COLCRYS-Full-Prescribing—Information.pdf; pp. 1-5 ; revised Sep. 2009; printed Oct. 19, 2009.
Herrewege, et al; A Dual Chamber Model of Female Cervical Mucosa for the Study of HIV Transmission and for the Evaluation of Candidate HIV Microbicides; Antiviral Research; 74; pp. 111-124; (2007).
Lacy et al; Lexi-Comp's Clinical Reference Library, Drug Information Handbook, 7th Ed., pp. 108-109 and 292-293; 1999-2000.
Terkeltaub, Robert A.; “Colchicine Update: 2008”; Seminars in Arthritis and Rheumatism; VA Medical Center, University of C alifornia, San Diego; 38(6); pp. 411-419; (2009).
Wang et al; “HMG-CoA Reductase Inhibitors (Statins) Characterized as Direct Inhibitors of P-Glycoprotein”; Pharmaceutical Research; vol. 18(6); pp. 800-806; (2001).
Ben-Chetrit; Colchicine: 1998 Update; Seminars in Arthritis and Rheumatism; 28; pp. 48-59; (1998).
DRUGS.COM; “Colchicine and ritonavir interactions”, printed Jan. 5, 2009; “colchicine”, printed Jan. 9, 2009; and “ritonavir”, printed Jan. 9, 2009.
Horn, et al.; “Life-Threatening Colchicine Drug Interactions”; Pharmacy Times; pp. 111; (May 2006).
Hsu, et al; “Ritonavir; Clinical Pharmacokinetics and Interactions with Other Anti-HIV Agents”; Clinical Pharmacokinet; 35; pp. 275-291; (1998).
Niel, et al.; “Colchicine Today”; Joint Bone Spine; 73; pp. 672-678; (2006).
Perez-Ruiz, et al.; “Optimisation of the Treatment of Acute Gout”; BioDrugs; 13; pp. 415-423; (2000).
Terkeltaub, Robert A.; “Gout”; The New England Journal of Medicine; 349; pp. 1647-1655; (2003).
Van Der Velden, et al; “Colchicine-Induced Neuromyopathy in a Patient With Chronic Renal Failure: The Role of Clarithromycin”; Netherlands, The Journal of Medicine; 66; pp. 204-206; (2008).
Zhou, et. al; “Clinical Outcomes and Management of Mechanism-Based Inhibition of Cytochrome P450 3A4”; Therapeutics and Clinical Risk Management; 1; pp. 3-13; (2005).
Keven et al., “Long-term outcome of renal transplantation in patients with familial Mediterranean Fever Amyloidsis: A single-center experience”; Transplantation Proceedings; 36; pp. 2632-2634; (2004).
Leikin et al., “Colchicine” Poisoning and Toxicology Handbook, Fourth Edition, p. 216; (2007).
Terkeltaub, et al.; “Comparison of Low-Dose vs High-Dose Oral Colchicine Regimens in Patients with Gout Flares”; Presentation at the American College of Rheumatology Scientific Meeting; San Francisco, CA; Oct. 24-29; (2008a).
Terkeltaub, et al.; “The Clinical Relevance of P-gp and CYP 3A4 on Colchicine Metabolism and Elimination”; Presentation at the American College of Rheumatology Scientific Meeting; San Francisco, CA; Oct. 24-29; (2008b).
Creighton, et al.; “Is Ritonavir Boosting Associated With Gout?”; International Journal of ST & AIDS; 16: 362-364; (2005).
Ogbru, Omudhome (www.medicinenet.com/colchicine/article.htm; 2 pages; (2008).
Rango; “Management of Gout With Colchicine”, http://www.theberries.ca/Archives/colchicine.html; 4 pages; available on line as of Jul. 5, 2003).
U.S. Appl. No. 12/858,667, filed Aug. 18, 2010; Non-Final Office Action dated Oct. 5, 2010; 32 pages.
Achtert et al. “Pharmacokinetics/bioavailability of colchicine in healthy male volunteers” Eur. J. Drug Metab. Pharmacokinet. 1989, 14(4): 317-322.
FDA; “Drugs”; Questions and Answers About FDA's Enforcement Action Unapproved Injectable Colchicine Products; http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Enforcement Action; printed Dec. 6, 2010.
FDA; “In Vivo Drug Metabolism/Drug Interaction Studies—Study Design, Data Analysis, and Recommendations for Dosing and Labeling”; Nov. 1999 (:FDA Guidance) 19 pages.
Sabourand, et al.; “Pharmacokinetics of Colchicine. A review of Experimental and Clinical Data”; 2 Gastroenterol (Suppl. 1)30; pp. 35-39; (1992).
AR Holding Company, Inc.
Cantor & Colburn LLP
Fetterolf Brandon J
Ricci Craig
LandOfFree
Methods for concomitant administration of colchicine and a... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for concomitant administration of colchicine and a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for concomitant administration of colchicine and a... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2692246